• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Neurotech International

Neurotech International

ASX:NTI

  • Home
  • Corporate
    • Board and Management
    • Corporate Directory
    • Corporate Governance
  • Development Programs
    • Biopharmaceutical Trials
    • Combination Therapy
    • Pathways to Commercialisation
    • Mente Technology
  • Investors
    • Investor Dashboard
    • ASX Announcements
    • Company Reports
    • Presentations
    • Research
    • News & Media
  • Contact

Stockhead

Neurotech International is anticipating results from its extended world first study of a medicinal cannabis product in children which could be a game-changer in autism treatment.

21 September 2022 News & MediaStockhead

Neurotech is anticipating results from its extended world first study of a medicinal cannabis product in children which could be a game-changer in autism treatment. Read the full story here.

Neurotech International appoints industry expert during key phase of growth

18 August 2022 News & MediaStockhead

Neurotech International has made key appointments and changes to its board as it focuses on its developing and commercialising neurological solutions, including a cannabis breakthrough for paediatric autism.

Neurotech eyes Phase II/III trial and FDA approval after cannabis breakthrough on paediatric autism

22 July 2022 News & MediaStockhead

Neurotech International (ASX:NTI) has recently announced ground-breaking results with respect to the safety, tolerability, and efficacy of NTI164 in Autism Spectrum Disorder (ASD) patients.

Neurotech study says cannabis could be key to helping kids on the spectrum reach potential

8 July 2022 News & MediaStockhead

Neurotech International (ASX:NTI) has released promising results from a Phase I/II clinical study of its proprietary NTI164 cannabis strain in paediatric Autism Spectrum Disorder (ASD).

Neurotech tackles the anguish of autism with low-THC cannabis treatment

1 July 2022 News & MediaStockhead

A medical dilemma in its own right – the modern treatment of the condition commonly known as ‘autism’ can come at a high cost and with debilitating side effects – something ASX-listed Neurotech International aims to change.

Weed Week: Cannabis-feed for chickens and cannabis campaigner nabs Queen’s Birthday honour

17 June 2022 News & MediaStockhead

The company recently reported significant development in the preclinical research of its lead asset program, NTI164 – a proprietary cannabis strain that contains high levels of unique minor cannabinoids and less than 0.3% THC, exclusively licensed from Dolce Cann Global.

ASX Health Stocks: Neurotech says its cannabis strain works well when combined with Diclofenac

9 June 2022 News & MediaStockhead

Neurotech International (ASX:NTI) has today reported significant development in the preclinical research of its lead asset program, NTI164.

Neurotech just started world’s first THC-less cannabis study in autistic children

6 May 2021 News & MediaStockhead

The Phase I/II clinical trial announced today is a groundbreaking study where medicinal cannabis containing little to no THC is being tested on autistic children.

Footer

Suite 5 CPC, 145 Stirling Highway
Nedlands WA 6009
Australia

moc.l1675269324anoit1675269324anret1675269324nihce1675269324torue1675269324n@ofn1675269324i1675269324

+61 (8) 9389 3130

Subscribe to our latest announcements

Name*
This field is for validation purposes and should be left unchanged.

Copyright © 2023 Neurotech International • Site by White Noise Communications

Download prospectus